Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy
Doody KM., Stanford SM., Sacchetti C., D. Svensson MN., Coles CH., Mitakidis N., Kiosses WB., Bartok B., Fos C., Cory E., Sah RL., Liu-Bryan R., Boyle DL., Arnett HA., Mustelin T., Corr M., Esko JD., Tremblay ML., Firestein GS., Aricescu AR., Bottini N.
Targeting joint-lining fibroblast-like synoviocytes reduces the severity of arthritis.